As new immunomodulatory therapies continue to be licensed for use in Multiple Sclerosis, it is important to remain vigilant for new, unexpected associations relating to these medications.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Brain MRI before/after gadolinium was stable with no new or enhancing lesions and no meningeal enhancement. Two months following daclizumab cessation, spirometry demonstrated moderate obstruction; FEV1 2.13 (62.3% predicted), FVC 3.62 (83.7% predicted), FEV1/FVC ratio 58.8%. At this point, all symptoms except the non-productive cough had resolved. No alternative aetiology was identified and a clinical diagnosis of sarcoidosis was made. Inhaled corticosteroids were commenced followed by a short trial of oral corticosteroids, both of which had no effect on the cough.
CT-PET 6-months following daclizumab cessation demonstrated reduction in lymph node uptake. Repeat spirometry 10-weeks following discontinuation of corticosteroids was normal; FEV1 3.01 (88% predicted), FVC 3.74 (86.5% predicted), FEV1/FVC ratio 80.5%.
Considering subjective and objective evidence of improvement following daclizumab cessation, it was reasoned that daclizumab was the probable cause and it was therefore permanently discontinued.
DISCUSSION
Sarcoidosis is a multi-system granulomatous disorder that most commonly affects the pulmonary and lymphatic systems. In most patients, granulomas resolve spontaneously or following appropriate therapy (e.g. corticosteroids with or without steroid sparing agents such as methotrexate). A minority of patients develop chronic progressive disease, characterised by persisting granulomas, which may undergo fibrosis, causing irreversible organ damage. In a review of daclizumab, the Center for Drug Evaluation and Research (a division of the U.S. Food and Drug Administration), with access to raw trial data, identified nine cases of sarcoidosis amongst various RRMS trial cohorts, with another four potential cases. Based on these nine confirmed cases, the incidence of sarcoidosis was estimated to be approximately 1.32/1,000 patient years compared to a reported rate in the general population of 1.0-35.5 per 100,000/year 6 . One case of sarcoidosis has also been reported in a patient treated off study with another form of daclizumab in adult T-cell leukaemia/lymphoma 7 .
The development of sarcoidosis has also been observed following the use of other disease modifying therapies. Several cases have been reported following the use of interferon-β, including specifically in patients being treated for multiple sclerosis 8 . There have also been reports of cases following the use of alemtuzumab 9 and natalizumab 10 in the treatment of other diseases; although to our knowledge, there are no reports in the literature of the development of sarcoidosis in patients treated with these medications for multiple sclerosis.
This case emphasises the need to be vigilant for unexpected associations when using novel immunomodulatory therapies. 
